Fanconi Anemia Subtype A clinical trials

Explore recruiting fanconi anemia subtype a clinical trials.

Also recruiting in Europe

Fanconi Anemia Subtype A trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A: FANCOLEN-I

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Fanconi Anemia Subtype A trials by city

Fanconi Anemia Subtype A in Toronto Fanconi Anemia Subtype A in Vancouver Fanconi Anemia Subtype A in Montreal Fanconi Anemia Subtype A in Calgary Fanconi Anemia Subtype A in Edmonton Fanconi Anemia Subtype A in Ottawa Fanconi Anemia Subtype A in Winnipeg Fanconi Anemia Subtype A in Quebec City Fanconi Anemia Subtype A in Hamilton Fanconi Anemia Subtype A in Kitchener Fanconi Anemia Subtype A in London Fanconi Anemia Subtype A in Halifax Fanconi Anemia Subtype A in New York Fanconi Anemia Subtype A in Los Angeles Fanconi Anemia Subtype A in Chicago Fanconi Anemia Subtype A in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease